Navignostics

1. Executive Summary (Confidence: High)

Navignostics is a high-growth precision medicine company that is revolutionizing cancer diagnostics through the application of spatial single-cell proteomics. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, the company provides a paradigm shift from traditional "bulk" sequencing to high-resolution protein imaging. By determining the exact cellular composition and interactions within a single tumor tissue section, Navignostics identifies the optimal therapy for individual patients, particularly those in late-stage settings where standard treatments have failed. The company’s clinical utility was validated in 2025 by a landmark Nature Medicine study showing that its profiling technology tripled the disease control rate for heavily pretreated melanoma patients. With a CHF 7.5 million seed round led by Bruker and a strategic partnership with Standard BioTools, Navignostics is scaling toward global distribution by early 2026.18